|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 471/04 | (2006.01) |
| A61P 35/00 | (2006.01) | ||
| A61P 37/00 | (2006.01) | ||
| A61K 31/437 | (2006.01) |
| (11) | Number of the document | 3510034 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18707612.0 |
| Date of filing the European patent application | 2018-02-16 | |
| (97) | Date of publication of the European application | 2019-07-17 |
| (45) | Date of publication and mention of the grant of the patent | 2020-04-22 |
| (46) | Date of publication of the claims translation | 2020-08-10 |
| (86) | Number | PCT/US2018/018484 |
| Date | 2018-02-16 |
| (87) | Number | WO 2018/152396 |
| Date | 2018-08-23 |
| (30) | Number | Date | Country code |
| 201762460677 P | 2017-02-17 | US | |
| 201762490881 P | 2017-04-27 | US | |
| 201762573991 P | 2017-10-18 | US |
| (72) |
GLICK, Gary, US
GHOSH, Shomir, US
ROUSH, William R., US
OLHAVA, Edward James, US
O`MALLEY, Daniel, US
|
| (73) |
Innate Tumor Immunity, Inc.,
Route 206 and Province Line Road, Princeton, New Jersey 08543,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Pakeistieji imidazochinolinai, kaip NLRP3 moduliatoriai |
| SUBSTITUTED IMIDAZO-QUINOLINES AS NLRP3 MODULATORS |
| Payment date | Validity (years) | Amount | |
| 2025-01-02 | 8 | 185.00 EUR |
| 2026-02-16 |